Full-Service Provider for the Microbial Production of Pharmaceutical Proteins
Customized Vaccine Development at Our mRNA Technical Center
Wacker Biotech GmbH is a leading producer of biopharmaceuticals. Headquartered in Jena, it operates a site in Halle (Saale), which has over 20 years of experience in the industry. Here the WACKER Group subsidiary develops and produces therapeutic proteins with production of mRNA-based active ingredients to be added in the future. Halle is considered one of Europe’s leading life sciences hubs.
In addition to medium-sized companies, the audited multi-purpose plant also supplies internationally active pharmaceutical and biotechnology companies. Its service portfolio includes a protein refolding method for manufacturing proteins that cannot be produced in their active form in bacterial cells.
Its combination of innovation, quality and efficiency has established Wacker Biotech as a reliable partner for the biopharmaceuticals industry. The new mRNA competence center to be erected by 2024 will focus on the production of active ingredients and vaccines for various disease indications. Our expertise in this field was honored with the award of a pandemic readiness contract for mRNA vaccines by the German government.
WACKER is proud to do its part in making sure patients throughout the world have access to life-saving medicines. This also includes Halle’s production of reteplase, which is the active agent in the Retavase, a brand of medication used for treating acute myocardial infarction by dissolving blood clots.
Jobs & Careers
Employees on campus have access to two cafeterias, a JobRad bicycle leasing program and good connections to public transit. Our interdepartmental projects promote equal opportunity, teamwork and camaraderie. A committed, on-site employee council protects and represents the interests of employees. Welcome to the WACKER team!
Site-Specific Facts & Figures
- Name: Wacker Biotech GmbH
- Site: Halle
- Employees: approx. 250
- Products: recombinant proteins (contract manufacturing), pharmaceutical actives for clinical testing and for the commercial market, mRNA drug product intermediates manufacturing (starting in 2024)
- The facility is certified in accordance with Good Manufacturing Practice (GMP) and complies with the requirements stipulated by the European and US drug-approval authorities (EMA and FDA, respectively)